Argenica Therapeutics Company Description

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia.

Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury.

Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

Argenica Therapeutics Limited

Country	Australia
Founded	2019
Industry	Biotechnology
Sector	Healthcare
CEO	Liz Dallimore

Contact Details

Address: 117 Broadway Nedlands, Washington 6009 Australia
Phone	61 8 9329 3396
Website	argenica.com.au

Stock Details

Ticker Symbol	AGN
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000150328
SIC Code	2834

Key Executives

Name	Position
Emma Waldon	Chief Financial Officer and Company Secretary
Prof. Bruno Philip Meloni	Chief Scientific Officer